<unk> (oral) is a retinoic acid that is FDA approved for the treatment of acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include malaise, shivering, hemorrhage, infections, peripheral edema, pain, chest discomfort, and edema.
Tretinoin 
Alitretinoin
Isotretinoin
Halobetasol
Clobetasol
Clobetasol propionate
Etretinate
Psoralen